Nucleis Radiopharmaceuticals

Nucleis is a radiopharmaceutical company specializing in the manufacturing and distribution of radiopharmaceutical drugs for diagnostic and therapy monitoring, with a focus on Positron Emission Tomography (PET). The company was established in June 2017 as a spin-off from the University of Liège's Cyclotron Research Centre in Belgium, inheriting over 15 years of experience in the field. Nucleis' core business involves the production of market-authorized drugs and investigational medicinal products for PET imaging. The company holds marketing authorization for fludeoxyglucose (18F), commonly known as FDG, in Belgium, The Netherlands, Luxembourg, France, and Germany. Nucleis also serves as a Contract Manufacturing Organization (CMO), producing radiopharmaceuticals for other companies. As part of its CMO activities, Nucleis is registered as a manufacturer for several marketing authorizations granted by the European Medicines Agency (EMA) and is involved in various Investigational Medicinal Product Dossiers (IMPDs). The company aims to continuously expand its portfolio of diagnostic tools to support the development of innovative therapies.

Key customers and partnerships

Nucleis delivers its products and services to customers in five countries: Belgium, France, Germany, the Netherlands, and Luxembourg. The company has established itself as an authorized manufacturer for GE healthcare Radiopharmaceuticals and Blue Earth Diagnostics. Nucleis maintains a strong partnership with the Cyclotron Research Centre for the development of new tracers and R&D activities, providing access to specialized resources and facilities. As part of its CMO activities, Nucleis collaborates with several companies, including GE healthcare and Blue Earth Diagnostics, manufacturing radiopharmaceutical drugs with marketing authorization such as Vizamyl for Alzheimer's disease and Axumin for prostate cancer, as well as investigational medicinal products like 18F-Flurpiridaz for heart diseases.